ContextVision partners with University of Waterloo in Canada and InPhase Solutions AS in Norway to advance ultrasound diagnostics for MASLD

ContextVision, a global leader in medical imaging solutions, is strengthening its research ecosystem by establishing key partnerships with ultrasound data scientists and clinical experts. These collaborations will accelerate the development of ContextVision’s AI-based solutions capable of interpreting organ-specific ultrasound imaging datasets, with a first focus on optimizing data quality for the diagnosis of metabolic dysfunction-associated steatotic liver disease (MASLD).

As part of this initiative, ContextVision has signed a research agreement with the University of Waterloo’s Laboratory on Innovative Technology in Medical Ultrasound (LITMUS) in Canada. This collaboration will augment technical and clinical expertise in ultrasound to evolve advanced liver imaging.

Additionally, the company has partnered with InPhase Solutions AS, a Norway-based expert in ultrasound technology development and consultancy. InPhase will provide specialized support to enhance ContextVision’s internal R&D efforts, strengthening its capabilities in quantitative imaging and AI-powered ultrasound technologies.

These partnerships are part of ContextVision’s broader strategy to engage with global ultrasound players, securing additional expertise and analytical support, and to drive advancements in data quality and clinical applications for ultrasound-based solutions.

Strengthening the Ecosystem for Liver Disease Diagnostics

“This project connects all the right dots: the increasing importance of easy-access liver disease diagnostics, a state-of-the-art ultrasonic dataset, and AI-based analysis,” said Marco M. Voormolen, CEO of InPhase Solutions AS. “We at InPhase Solutions are most excited to be part of this initiative.”

“This partnership is an excellent example of academia and industry working together to bring potentially life-changing solutions to clinical practice,” said Dr. Alfred Yu, principal investigator of LITMUS and a professor of biomedical engineering in Waterloo’s Faculty of Engineering. “We are looking forward to applying our next-generation quantitative ultrasound techniques as part of this collaboration to enhance MASLD diagnostics.”

 
Expanding the Data Quality Initiative

ContextVision’s expansion into data quality represents a strategic shift beyond its established role in image quality. In January 2025, the company announced its first major research partnership in this field, collaborating with the University of Washington’s School of Medicine to advance MASLD diagnostics by developing ultrasound-based biomarkers. The new agreements with LITMUS and InPhase Solutions build upon this foundation, further solidifying ContextVision’s commitment to improving ultrasound-based disease quantification.

“Building a strong research ecosystem is key to advancing the next generation of ultrasound diagnostics,” said Gerald Pötzsch, CEO of ContextVision. “By bringing together top-tier academic expertise and industry-leading technological capabilities, we are creating the foundation for breakthrough innovations in liver disease quantification. These partnerships mark the beginning of a growing network that will expand further in the near future.”

With MASLD affecting an estimated 25% of the global population and rising[1], there is a growing demand for accessible, non-invasive diagnostic solutions. ContextVision’s work in data quality and quantitative imaging aims to bridge this gap, leveraging AI-driven analysis to enhance diagnostic precision and improve patient outcomes.

For more information, please contact:
Gerald Pötzsch
Chief Executive Officer, ContextVision
[email protected]

About ContextVision
ContextVision is a software company specialized in image analysis and artificial intelligence. As the global market leader within image enhancement, we are a trusted partner to leading manufacturers of ultrasound, X-ray and MRI equipment around the world. Our expertise is to develop powerful software products, based on proprietary technology and artificial intelligence for image-based applications. Our cutting-edge technology helps clinicians accurately interpret medical images, a crucial foundation for better diagnosis and treatment. The company, established in 1983, is based in Sweden with local representation in the U.S., Japan, China and Korea. ContextVision is listed on the Oslo Stock Exchange under the ticker CONTX.